ข้ามไปยังเนื้อหาหลัก

ENGLISH · EVIDENCE OVERVIEW

YK-11
evidence profile

Experimental steroidal androgen-receptor partial agonist / SARM-class candidate. This page provides a concise English boundary and links back to the complete source-rich Thai profile.

YK-11: conceptual scientific illustration for Clinical / Endocrine Pharmacology
VISUAL GUIDE · YK-11

Clinical / Endocrine Pharmacology

Conceptual educational illustration. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

YK-11 is an experimental steroidal androgen-receptor partial agonist commonly placed in the SARM class; it is not follistatin, a myostatin-neutralising biologic or testosterone. The frequently cited follistatin finding comes from mouse C2C12 cells, not a human efficacy trial. Rat research reported neurochemical and memory-related changes. FDA states that no SARM is approved and discusses a stroke report involving a tested YK-11-labelled product, without proving universal product identity or sole causation. WADA prohibits YK-11 at all times.

01

ENTITY FACTS

What should readers identify first?

MOLECULEYK-11
PHARMACOLOGYExperimental steroidal androgen-receptor partial agonist / SARM-class candidate
PRIMECORE CLASSC
EVIDENCE GRADEE
RESEARCH TOPICClinical / Endocrine Pharmacology
LAST REVIEWED2026-09-01
02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is YK-11?

YK-11 is described pharmacologically as Experimental steroidal androgen-receptor partial agonist / SARM-class candidate. YK-11 is an experimental steroidal androgen-receptor partial agonist commonly placed in the SARM class; it is not follistatin, a myostatin-neutralising biologic or testosterone. The frequently cited follistatin finding comes from mouse C2C12 cells, not a human efficacy trial. Rat research reported neurochemical and memory-related changes. FDA states that no SARM is approved and discusses a stroke report involving a tested YK-11-labelled product, without proving universal product identity or sole causation. WADA prohibits YK-11 at all times.

Does YK-11 have strong evidence?

PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is YK-11 approved everywhere?

No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

LINE · สอบถามข้อมูลทั่วไปติดต่อฝ่ายข้อมูลทั่วไปLINE · GENERAL SUPPORTGeneral enquiries@primecoreสำหรับข้อมูลทั่วไปเท่านั้น · ไม่มีบริการด้านการขายหรือคำแนะนำทางการแพทย์General information only · No sales or medical advice